After being spurned at the FDA, PTC buys a controversial Duchenne MD therapy from Marathon
After being stung by a fierce backlash over its plans to sell a cheap, old steroid for Duchenne muscular dystrophy for $89,000 a year, Marathon …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
